Clinical Trial Update: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing SOK583A1 to Eylea in neovascular age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• SOK583A1

Snippet

Sponsor: Sandoz | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2024-03-26